Entrada Therapeutics, Inc. (TRDA)
| Market Cap | 340.59M |
| Revenue (ttm) | 210.78M |
| Net Income (ttm) | 65.63M |
| Shares Out | 35.63M |
| EPS (ttm) | 1.68 |
| PE Ratio | 5.69 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 61,400 |
| Open | 9.85 |
| Previous Close | 9.96 |
| Day's Range | 9.51 - 9.90 |
| 52-Week Range | 9.51 - 21.79 |
| Beta | -0.14 |
| Analysts | Strong Buy |
| Price Target | 25.67 (+168.52%) |
| Earnings Date | May 6, 2025 |
About TRDA
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company’s EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides. Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for TRDA stock is "Strong Buy." The 12-month stock price forecast is $25.67, which is an increase of 168.52% from the latest price.
News
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon s...
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical s...
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently receive...
Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside
Entrada Therapeutics addresses intracellular drug delivery challenges with its Endosomal Escape Vehicle platform, positioning itself uniquely in the biotech sector. Strong financials with $449.3 milli...
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
– Company on track to initiate ELEVATE-44-201 in Q2 2025 – – ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU, with regulatory discussions ongoing – BOSTON,...
Azenta Announces the Election of Dipal Doshi to its Board of Directors
BURLINGTON, Mass. , Jan. 30, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) and a recognized leader i...
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class ...
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
– Additional positive data from the Company's completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports the planned Q4 2024 global regulatory filings for a Pha...
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellul...
āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors
BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announ...
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
- Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration of...
Entrada Therapeutics Announces $100 Million Registered Direct Offering
– The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm – – The offering was led by a U.S.-based healt...
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physic...
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class ...
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class o...
Entrada Therapeutics Reports First Quarter 2024 Financial Results
– Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 –
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
– Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 – – Completed dosing for third cohort of Phase 1 ...
Entrada Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular ...
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
– Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 – – ENTR-601-44 clinical development program remains on track with data readout expected in second hal...
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
– Initiation of Phase 1 clinical trial marks Entrada's transition into a clinical company – – Data anticipated in the second half of 2024 – BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeut...
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escap...
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the United Kingdom in September 2023 –
Entrada Therapeutics: Early Stage But Interesting
Entrada Therapeutics is developing endosomal escape vehicles (EEV) to deliver oligonucleotides for neuromuscular diseases. Despite having no clinical data, the company has a market cap of nearly $600m...
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
BOSTON, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosoma...
Entrada Therapeutics Reports First Quarter 2023 Financial Results
- $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 - - Cash runway into the second half of 2025 -